Albumin Binding Function: The Potential Earliest Indicator for Liver Function Damage

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2017 Jan 20

PMID 28101103

Citations 7

Authors

Penglei Ge

Huayu Yang

Jingfen Lu

Wenjun Liao

Shunda Du

Yingli Xu

Haifeng Xu

Haitao Zhao

Xin Lu

Xinting Sang

Shouxian Zhong

Jiefu Huang

Yilei Mao

Affiliations

Soon will be listed here.

Abstract

. Currently there is no indicator that can evaluate actual liver lesion for early stages of viral hepatitis, nonalcoholic fatty liver disease (NAFLD), and cirrhosis. Aim of this study was to investigate if albumin binding function could better reflect liver function in these liver diseases. . An observational study was performed on 193 patients with early NAFLD, viral hepatitis, and cirrhosis. Cirrhosis patients were separated according to Child-Pugh score into A, B, and C subgroup. Albumin metal ion binding capacity (Ischemia-modified albumin transformed, IMAT) and fatty acid binding capacity (total binding sites, TBS) were detected. . Both IMAT and TBS were significantly decreased in patients with NAFLD and early hepatitis. In hepatitis group, they declined prior to changes of liver enzymes. IMAT was significantly higher in cirrhosis Child-Pugh class A group than hepatitis patients and decreased in Child-Pugh class B and class C patients. Both IMAT/albumin and TBS/albumin decreased significantly in hepatitis and NAFLD group patients. . This is the first study to discover changes of albumin metal ion and fatty acid binding capacities prior to conventional biomarkers for liver damage in early stage of liver diseases. They may become potential earliest sensitive indicators for liver function evaluation.

Citing Articles

Biomarkers of Hepatic Toxicity: An Overview.

Thakur S, Kumar V, Das R, Sharma V, Mehta D Curr Ther Res Clin Exp. 2024; 100:100737.

PMID: 38860148 PMC: 11163176. DOI: 10.1016/j.curtheres.2024.100737.

A Nuphar lutea plant active ingredient, 6,6'-dihydroxythiobinupharidine, ameliorates kidney damage and inflammation in a mouse model of chronic kidney disease.

Landau D, Khalilia J, Arazi E, Tobar A, Benharroch D, Golan-Goldhirsh A Sci Rep. 2024; 14(1):7577.

PMID: 38555397 PMC: 10981724. DOI: 10.1038/s41598-024-58055-1.

Albumin, an interesting and functionally diverse protein, varies from 'native' to 'effective' (Review).

Wu N, Liu T, Tian M, Liu C, Ma S, Cao H Mol Med Rep. 2023; 29(2).

PMID: 38099350 PMC: 10784728. DOI: 10.3892/mmr.2023.13147.

Association between serum uric acid-to-creatinine ratio and non-alcoholic fatty liver disease: a cross-sectional study in Chinese non-obese people with a normal range of low-density lipoprotein cholesterol.

Wang X, Han Y, Liu Y, Hu H BMC Gastroenterol. 2022; 22(1):419.

PMID: 36104672 PMC: 9472393. DOI: 10.1186/s12876-022-02500-w.

Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease.

Sun L, Wang Q, Liu M, Xu G, Yin H, Wang D Endocrine. 2020; 69(2):294-302.

PMID: 32399892 DOI: 10.1007/s12020-020-02319-z.

References

Field K, Dow C, Michael M . Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol. 2008; 9(11):1092-101. DOI: 10.1016/S1470-2045(08)70279-1. View

Ge P, Du S, Mao Y . Advances in preoperative assessment of liver function. Hepatobiliary Pancreat Dis Int. 2014; 13(4):361-70. DOI: 10.1016/s1499-3872(14)60267-8. View

Cheung T, Lo C . Laparoscopic liver resection for hepatocellular carcinoma in patients with cirrhosis. Hepatobiliary Surg Nutr. 2016; 4(6):406-10. PMC: 4689690. DOI: 10.3978/j.issn.2304-3881.2015.06.12. View

Fan J, Farrell G . Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2008; 50(1):204-10. DOI: 10.1016/j.jhep.2008.10.010. View

Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y . Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol. 2015; 50(4):364-77. DOI: 10.1007/s00535-015-1050-7. View

Oettl K, Birner-Gruenberger R, Spindelboeck W, Stueger H, Dorn L, Stadlbauer V . Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol. 2013; 59(5):978-83. DOI: 10.1016/j.jhep.2013.06.013. View

Linhart K, Glassen K, Peccerella T, Waldherr R, Linhart H, Bartsch H . The generation of carcinogenic etheno-DNA adducts in the liver of patients with nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2015; 4(2):117-23. PMC: 4405412. DOI: 10.3978/j.issn.2304-3881.2015.01.14. View

Jalan R, Schnurr K, Mookerjee R, Sen S, Cheshire L, Hodges S . Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology. 2009; 50(2):555-64. DOI: 10.1002/hep.22913. View

Chalasani N, Younossi Z, Lavine J, Diehl A, Brunt E, Cusi K . The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55(6):2005-23. DOI: 10.1002/hep.25762. View

10.

Vernon G, Baranova A, Younossi Z . Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34(3):274-85. DOI: 10.1111/j.1365-2036.2011.04724.x. View

11.

Bar-Or D, Lau E, Winkler J . A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000; 19(4):311-5. DOI: 10.1016/s0736-4679(00)00255-9. View

12.

Croagh C, Lubel J . Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol. 2014; 20(30):10395-404. PMC: 4130846. DOI: 10.3748/wjg.v20.i30.10395. View

13.

Kao J, Chen P, Chen D . Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv Cancer Res. 2010; 108:21-72. DOI: 10.1016/B978-0-12-380888-2.00002-9. View

14.

Than N, Newsome P . A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015; 239(1):192-202. DOI: 10.1016/j.atherosclerosis.2015.01.001. View

15.

Kazmierczak S, Gurachevsky A, Matthes G, Muravsky V . Electron spin resonance spectroscopy of serum albumin: a novel new test for cancer diagnosis and monitoring. Clin Chem. 2006; 52(11):2129-34. DOI: 10.1373/clinchem.2006.073148. View

16.

Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R . Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013; 58(5):1836-46. DOI: 10.1002/hep.26338. View

17.

Junk M, Spiess H, Hinderberger D . The distribution of fatty acids reveals the functional structure of human serum albumin. Angew Chem Int Ed Engl. 2010; 49(46):8755-9. DOI: 10.1002/anie.201003495. View

18.

Zezos P, Renner E . Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol. 2014; 20(42):15532-8. PMC: 4229518. DOI: 10.3748/wjg.v20.i42.15532. View

19.

. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010; 53(3):397-417. DOI: 10.1016/j.jhep.2010.05.004. View

20.

Hoekstra L, de Graaf W, Nibourg G, Heger M, Bennink R, Stieger B . Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg. 2012; 257(1):27-36. DOI: 10.1097/SLA.0b013e31825d5d47. View